Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial - Concepedia

Concepedia

Publication | Open Access

Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial

DOI Full Paper Access

192

Citations

16

References

2019

Year

Denis Moro‐Sibilot, Nathalie Cozic, M. Pérol, Julien Mazières, Josiane Otto, P.-J. Souquet, Rastislav Bahleda, Marie Wislez, Gérard Zalcman, Sophie de Guibert,

Annals of Oncology

Medicinal ChemistryRos1-positive NsclcMedicineClinical TrialsPharmacotherapyPharmacologyDrug Discovery

References

	Year	Citations

Page 1